Session Information
Date: Tuesday, June 6, 2017
Session Title: Parkinson's Disease: Pathophysiology
Session Time: 1:45pm-3:15pm
Location: Exhibit Hall C
Objective: To evaluate cerebrospinal fluid (CSF) levels of proteins associated with neuropathological inclusions and ratios among them and CSF and plasma levels of inflammation-related proteins as potential biomarkers for PD diagnosis or progression. Besides our own cohort, Parkinson’s Progression Markers Initiative (PPMI) dataset was used as a replication cohort.
Background: Despite increasing efforts, no CSF or plasma biomarker has been validated for diagnosis or progression of PD.
Methods: CSF levels of α-synuclein, amyloid-ß1-42 (Aß1-42), total tau (T-Tau) and threonine-181 phosphorilated tau (P-Tau), as well as CSF and plasmatic levels of cytokines (IL-1ß, IL-2, IL-6, IFNγ, and TNF-α) were studied in 40 PD patients and 40 healthy controls. Plasmatic levels of cytokines were measured in 51 patients and 26 aditional controls. We also explored the PPMI dataset as a replication cohort.
Results: Controlling for age, the CSF levels of α-synuclein (p=0.007) and Aß1-42 (p=0.048) were lower and levels of TNF-α (p=0.021) higher in PD patients than in controls. The T-Tau/α-synuclein (p<0.001), P-Tau/α-synuclein (p<0.001), T-Tau/Aß1-42 + α-synuclein (p=0.005) and P-Tau/Aß1-42 + α-synuclein (p=0.001) ratios were higher in patients. The best area under the curve value was obtained for the P-Tau/α-synuclein ratio alone (0.86) and when combined with TNF-α in CSF (0.91; sensitivity 92.9%, specificity 75% for a cut-off value of ≤0.71). In the PPMI database, in keeping with our results, P-Tau/α-synuclein (p=0.030) and P-Tau/Aß1-42+α-synuclein (p=0.034) were higher in patients than in controls. Plasma cytokines did not differ between groups, although the IL-6 levels were, adjusted for age, positively correlated with the UPDRS I (ß=0.490; p=0.002), II (ß=0.492; p<0.001), and III (ß=0.367; p=0.020) scores.
Conclusions: The CSF P-Tau/α-synuclein ratio alone and combined with TNF-α might serve as biomarkers to diagnose PD. Plasma IL-6 could aid to monitor PD progression.
To cite this abstract in AMA style:
M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jimenez-Urbieta, R. Dacosta-Aguayo, I. Navalpotro-Gómez, J. Ruiz-Martínez, A. Bergareche, J. Martí-Massó, P. Martínez-Lage, A. Izagirre, M. Rodríguez-Oroz. The value of the Tau/α-synuclein ratio and TNF-α in cerebrospinal fluid, and of plasma IL-6, in the diagnosis and prognosis of Parkinson’s disease [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/the-value-of-the-tau%ce%b1-synuclein-ratio-and-tnf-%ce%b1-in-cerebrospinal-fluid-and-of-plasma-il-6-in-the-diagnosis-and-prognosis-of-parkinsons-disease/. Accessed November 22, 2024.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-value-of-the-tau%ce%b1-synuclein-ratio-and-tnf-%ce%b1-in-cerebrospinal-fluid-and-of-plasma-il-6-in-the-diagnosis-and-prognosis-of-parkinsons-disease/